Last reviewed · How we verify
NCT03874455
Tazemetostat Expanded Access Program for Adults With Solid Tumors
trial testing Tazemetostat in Epithelioid Sarcoma (Ex-US Only). No longer available.
Quick facts
| Lead sponsor | Epizyme, Inc. |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Tazemetostat (tazemetostat) — full drug profile →
Conditions studied
- Epithelioid Sarcoma (Ex-US Only) — all drugs for Epithelioid Sarcoma (Ex-US Only) →
- Spindle Cell Sarcoma — all drugs for Spindle Cell Sarcoma →
- Sinonasal Carcinoma — all drugs for Sinonasal Carcinoma →
- Small Cell Carcinoma of the Ovary Hypercalcemic Type — all drugs for Small Cell Carcinoma of the Ovary Hypercalcemic Type →
Sponsor
Epizyme, Inc. — full company profile →
Who can join
18 and older, any sex, with Epithelioid Sarcoma (Ex-US Only) or Spindle Cell Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed under "conditions" below are not eligible for the tazemetostat EAP.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The roles of EZH2 in cancer and its inhibitors.
Liu Y, Yang Q. · · 2023 · cited 100× · PMID 37148376 · DOI 10.1007/s12032-023-02025-6 -
Genomic Amplification and Functional Dependency of the Gamma Actin Gene <i>ACTG1</i> in Uterine Cancer.
Richter C, Mayhew D, Rennhack JP, So J, et al · · 2020 · cited 21× · PMID 33217970 · DOI 10.3390/ijms21228690 -
Polycomb group proteins in cancer: multifaceted functions and strategies for modulation.
Wang S, C Ordonez-Rubiano S, Dhiman A, Jiao G, et al · · 2021 · cited 19× · PMID 34617019 · DOI 10.1093/narcan/zcab039 -
Histone Modifying Enzymes in Gynaecological Cancers.
Ramarao-Milne P, Kondrashova O, Barry S, Hooper JD, et al · · 2021 · cited 9× · PMID 33669182 · DOI 10.3390/cancers13040816 -
Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in Therapy.
Lesovaya EA, Fetisov TI, Bokhyan BY, Maksimova VP, et al · · 2024 · cited 7× · PMID 39451213 · DOI 10.3390/cells13201695 -
New Prospects for Molecular Targets for Chordomas.
Ozair MZ, Shah PP, Mathios D, Lim M, et al · · 2020 · cited 7× · PMID 32147018 · DOI 10.1016/j.nec.2019.11.004 -
Use of DNA methylation patterns for early detection and management of lung cancer: Are we there yet?
Kontic M, Markovic F. · · 2025 · cited 4× · PMID 40191732 · DOI 10.32604/or.2024.057231 -
H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets.
Burlibasa L, Nicu AT, Chifiriuc MC, Medar C, et al · · 2023 · cited 4× · PMID 37228649 · DOI 10.3389/fcell.2023.1181764
Verify or expand the search:
- PubMed search for NCT03874455
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tazemetostat
Trials testing the same drug.
- NCT06575686 — Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · Phase 2 · suspended
- NCT06692452 — Tazemetostat Plus CHOP in 1L T-cell Lymphoma · Phase 2 · withdrawn
- NCT06242834 — Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggres · Phase 2 · active not recruiting
- NCT05983965 — Study of Tazemetostat in Lymphoid Malignancies · Phase 1 · terminated
- NCT05151588 — Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma · Phase 2 · not yet recruiting
Other Epizyme, Inc. trials
Trials by the same sponsor.
- NCT06068881 — A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lym · Phase 2 · withdrawn
- NCT05121103 — A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With R · Phase 1 · terminated
- NCT05205252 — A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. · Phase 1, PHASE2 · withdrawn
- NCT04762160 — SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicula · Phase 2 · terminated
- NCT04224493 — A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenal · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03874455 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Epizyme, Inc.
- Last refreshed: 22 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03874455.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing